Be careful what you wish for:
Canadian and US Think Tanks Release Joint Evaluation on Universal Health Care in Maryland
Experts’ Corner: Parallel Imports Are Not a Cure For America’s Prescription Drug Access Problem
The Stockholm Network turned to AIMS Sernior Fellow Brian Ferguson for expert commentary on the presecription drug re-importation issue facing the United States.
A Pill Too Hard to Swallow: The US can’t solve its prescription drug woes at the cost of Europe or Canada
AIMS President Brian Lee Crowley highlights the problems of drug re-importation schemes ... and Europe's hypocrisy in condemning American plans to do so.
U.S. lobby group slams drug trade with Canada
AIMS' recent report, "Drug Re-Importation in North America and Europe: An Overview" is getting noticed on both sides of the Canada-U.S. border. The report, written by Brian Ferguson, AIMS Fellow in Health Care Economics, elicited the Pharmaceutical Research and Manufacturers of America to issue a statement warning Americans that foreign drugs aren't safe. AIMS Director of Research Ian Munro goes on to note that such plans may have an impact on the drug supply in Canada and cause shortages.
Should prescriptions travel borders?
A renewed look at drug re-importation
Drug Re-Importation in North America and Europe
The United States cannot solve its "Medicare donut hole" through Canada’s back door. That’s the conclusion of this health care paper by Brian Ferguson, AIMS Fellow in Health Care Economics and a professor of Economics at the University of Guelph. The paper points out that as Americans head into an election year, drug re-importation will likely become an issue, particularly with several states actively promoting the re-importation of prescription drugs from Canada as a method to control Medicare costs.
Drug coverage policies a prescription for disaster
In his regular fortnightly column, Charles Cirtwill examines prescription drug policy in Canada's public health care system, and has a few suggestions.
What Happened to Miracle Cures?
AIMS acting president Charles Cirtwill provides analysis into US pharmaceutical legislation in this op / ed requested by The American Spectator. Cirtwill points out that the legislation allowing re-importation of prescription drugs will not solve what ails the system. He demonstrates that comprehensive care analysis is necessary and that limiting debate or legislation to the cost of prescription drugs is “penny wise but pound foolish”.
Don’t overprescribe for catastrophic drugs
Appearing in various sources this article shows why a national pharmacare plan is not a realistic way to solve the catastrophic prescription drug coverage gap that affects only Atlantic Canada
Bad numbers don’t add up to good policy
The public-private debate is undermined by a misuse of health care data.